Analyst Research

Report Title Price
Provider: Sadif Analytics Prime
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Shanghai Fosun Pharmaceutical Group Co Ltd Announces Details for Sale of Assets to SELLAS Clinicals Holding AG by Sub-subsidiary


Wednesday, 23 Oct 2013 08:00pm EDT 

Shanghai Fosun Pharmaceutical Group Co Ltd announced that its Chongqing-based pharmaceutical research sub-subsidiary will sell intellectual properties as well as related development, commercialization, sales and license rights on Fotagliptin benzoate and Pan-HER Inhibitors owned by the sub-subsidiary and its subsidiary, for EUR 388 million to SELLAS Clinicals Holding AG.